^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG CLASS:

DDX5 degrader

Related drugs:
30d
FL118 Enhances Therapeutic Efficacy in Colorectal Cancer by Inhibiting the Homologous Recombination Repair Pathway through Survivin-RAD51 Downregulation. (PubMed, Cancers (Basel))
Given that SN38 is the active metabolite of irinotecan, FL118 reduces cell viability and RAD51 in SN38-resistant LOVO cells. Our findings provide effective insights into the antitumor activity of FL118 and its potential as a therapeutic agent for overcoming irinotecan resistance in CRC.
Journal
|
HRD (Homologous Recombination Deficiency) • RAD51 (RAD51 Homolog A) • BIRC5 (Baculoviral IAP repeat containing 5)
|
BIRC5 expression
|
irinotecan • FL118
7ms
FL118 Is a Potent Therapeutic Agent against Chronic Myeloid Leukemia Resistant to BCR-ABL Inhibitors through Targeting RNA Helicase DDX5. (PubMed, Int J Mol Sci)
Furthermore, FL118 potently induced apoptosis not only in Ba/F3 cells expressing BCR-ABL, but also in those expressing the BCR-ABL T315I mutant, which is resistant to BCR-ABL inhibitors. Collectively, these results revealed that DDX5 is a critical therapeutic target in CML and that FL118 is an effective candidate compound for the treatment of BCR-ABL inhibitor-resistant CML.
Journal
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • BIRC5 (Baculoviral IAP repeat containing 5) • CASP3 (Caspase 3) • DDX5 (DEAD-Box Helicase 5)
|
BIRC5 expression • BCR expression
|
FL118
7ms
FL118 for Treating Patients With Advanced Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)
P1, N=84, Not yet recruiting, Roswell Park Cancer Institute | Trial completion date: May 2027 --> Oct 2027 | Initiation date: Apr 2024 --> Oct 2024 | Trial primary completion date: May 2027 --> Oct 2027
Trial completion date • Trial initiation date • Trial primary completion date • Metastases
|
FL118